The current state of biomarker research for Friedreich's ataxia: A report from the 2018 FARA biomarker meeting

Ian A. Blair, Jennifer Farmer, Steven Hersch, Jane Larkindale, David R. Lynch, Jill Napierala, Marek Napierala, R. Payne, Sub H. Subramony

Research output: Contribution to journalArticle

Abstract

The 2018 FARA Biomarker Meeting highlighted the current state of development of biomarkers for Friedreich's ataxia. A mass spectroscopy assay to sensitively measure mature frataxin (reduction of which is the root cause of disease) is being developed. Biomarkers to monitor neurological disease progression include imaging, electrophysiological measures and measures of nerve function, which may be measured either in serum and/or through imaging-based technologies. Potential pharmacodynamic biomarkers include metabolic and protein biomarkers and markers of nerve damage. Cardiac imaging and serum biomarkers may reflect cardiac disease progression. Considerable progress has been made in the development of biomarkers for various contexts of use, but further work is needed in terms of larger longitudinal multisite studies, and identification of novel biomarkers for additional use case.

Original languageEnglish (US)
Article numberFSO398
JournalFuture Science OA
Volume5
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Friedreich Ataxia
Biomarkers
Research
Disease Progression
Serum
Longitudinal Studies
Heart Diseases
Mass Spectrometry
Technology

Keywords

  • biomarkers
  • drug development
  • Friedreich's ataxia

ASJC Scopus subject areas

  • Biotechnology

Cite this

Blair, I. A., Farmer, J., Hersch, S., Larkindale, J., Lynch, D. R., Napierala, J., ... Subramony, S. H. (2019). The current state of biomarker research for Friedreich's ataxia: A report from the 2018 FARA biomarker meeting. Future Science OA, 5(6), [FSO398]. https://doi.org/10.2144/fsoa-2019-0026

The current state of biomarker research for Friedreich's ataxia : A report from the 2018 FARA biomarker meeting. / Blair, Ian A.; Farmer, Jennifer; Hersch, Steven; Larkindale, Jane; Lynch, David R.; Napierala, Jill; Napierala, Marek; Payne, R.; Subramony, Sub H.

In: Future Science OA, Vol. 5, No. 6, FSO398, 01.01.2019.

Research output: Contribution to journalArticle

Blair, IA, Farmer, J, Hersch, S, Larkindale, J, Lynch, DR, Napierala, J, Napierala, M, Payne, R & Subramony, SH 2019, 'The current state of biomarker research for Friedreich's ataxia: A report from the 2018 FARA biomarker meeting', Future Science OA, vol. 5, no. 6, FSO398. https://doi.org/10.2144/fsoa-2019-0026
Blair, Ian A. ; Farmer, Jennifer ; Hersch, Steven ; Larkindale, Jane ; Lynch, David R. ; Napierala, Jill ; Napierala, Marek ; Payne, R. ; Subramony, Sub H. / The current state of biomarker research for Friedreich's ataxia : A report from the 2018 FARA biomarker meeting. In: Future Science OA. 2019 ; Vol. 5, No. 6.
@article{de4d62aa032648f1a9f5c3b9777d9bca,
title = "The current state of biomarker research for Friedreich's ataxia: A report from the 2018 FARA biomarker meeting",
abstract = "The 2018 FARA Biomarker Meeting highlighted the current state of development of biomarkers for Friedreich's ataxia. A mass spectroscopy assay to sensitively measure mature frataxin (reduction of which is the root cause of disease) is being developed. Biomarkers to monitor neurological disease progression include imaging, electrophysiological measures and measures of nerve function, which may be measured either in serum and/or through imaging-based technologies. Potential pharmacodynamic biomarkers include metabolic and protein biomarkers and markers of nerve damage. Cardiac imaging and serum biomarkers may reflect cardiac disease progression. Considerable progress has been made in the development of biomarkers for various contexts of use, but further work is needed in terms of larger longitudinal multisite studies, and identification of novel biomarkers for additional use case.",
keywords = "biomarkers, drug development, Friedreich's ataxia",
author = "Blair, {Ian A.} and Jennifer Farmer and Steven Hersch and Jane Larkindale and Lynch, {David R.} and Jill Napierala and Marek Napierala and R. Payne and Subramony, {Sub H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2144/fsoa-2019-0026",
language = "English (US)",
volume = "5",
journal = "Future Science OA",
issn = "2056-5623",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - The current state of biomarker research for Friedreich's ataxia

T2 - A report from the 2018 FARA biomarker meeting

AU - Blair, Ian A.

AU - Farmer, Jennifer

AU - Hersch, Steven

AU - Larkindale, Jane

AU - Lynch, David R.

AU - Napierala, Jill

AU - Napierala, Marek

AU - Payne, R.

AU - Subramony, Sub H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The 2018 FARA Biomarker Meeting highlighted the current state of development of biomarkers for Friedreich's ataxia. A mass spectroscopy assay to sensitively measure mature frataxin (reduction of which is the root cause of disease) is being developed. Biomarkers to monitor neurological disease progression include imaging, electrophysiological measures and measures of nerve function, which may be measured either in serum and/or through imaging-based technologies. Potential pharmacodynamic biomarkers include metabolic and protein biomarkers and markers of nerve damage. Cardiac imaging and serum biomarkers may reflect cardiac disease progression. Considerable progress has been made in the development of biomarkers for various contexts of use, but further work is needed in terms of larger longitudinal multisite studies, and identification of novel biomarkers for additional use case.

AB - The 2018 FARA Biomarker Meeting highlighted the current state of development of biomarkers for Friedreich's ataxia. A mass spectroscopy assay to sensitively measure mature frataxin (reduction of which is the root cause of disease) is being developed. Biomarkers to monitor neurological disease progression include imaging, electrophysiological measures and measures of nerve function, which may be measured either in serum and/or through imaging-based technologies. Potential pharmacodynamic biomarkers include metabolic and protein biomarkers and markers of nerve damage. Cardiac imaging and serum biomarkers may reflect cardiac disease progression. Considerable progress has been made in the development of biomarkers for various contexts of use, but further work is needed in terms of larger longitudinal multisite studies, and identification of novel biomarkers for additional use case.

KW - biomarkers

KW - drug development

KW - Friedreich's ataxia

UR - http://www.scopus.com/inward/record.url?scp=85068315549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068315549&partnerID=8YFLogxK

U2 - 10.2144/fsoa-2019-0026

DO - 10.2144/fsoa-2019-0026

M3 - Article

AN - SCOPUS:85068315549

VL - 5

JO - Future Science OA

JF - Future Science OA

SN - 2056-5623

IS - 6

M1 - FSO398

ER -